Tonix Lawsuit Triggers Up To 30 Months Of Delay For Generic TONMYA Approval
Tonix seeks to keep the competing drug’s approval from taking effect until the last asserted patent expires.
Tonix Pharmaceuticals, which sells and develops medicines, sued Friday over a proposed generic version of TONMYA, triggering a pause of up to 30 months in final FDA approval. The company said in its 8-K that the pause remains subject to exceptions and court orders.
A Fight Through Patent Expiration
Tonix sued Dr. Reddy’s Laboratories, the applicant seeking approval for the competing drug, in the United States District Court for the District of New Jersey. Tonix alleges that the generic application infringes certain patents protecting TONMYA.
The company wants the court to bar approval from taking effect until the last asserted patent expires. That request seeks protection tied to the patents’ expiration, while the statutory pause triggered by the lawsuit has a maximum duration of 30 months.
The dispute concerns TONMYA’s 2.8 mg cyclobenzaprine hydrochloride tablets, which dissolve under the tongue. Tonix received notice of Dr. Reddy’s application on October 1, 2026, a development it had previously made public.
Dr. Reddy’s challenged four patents listed for TONMYA in the FDA’s Orange Book, its reference for approved drugs. Its application included a Paragraph IV certification: the applicant’s position that the patents are invalid, cannot be enforced or would not be infringed by its generic product.
TONMYA Sales Are At Stake
TONMYA is approved for fibromyalgia in adults and launched on November 17, 2025. Tonix’s marketed medicines also include the acute migraine treatments Zembrace SymTouch, a sumatriptan injection, and Tosymra, a sumatriptan nasal spray.
Tonix’s annual report for 2025 described about 90 U.S. sales representatives promoting TONMYA. The company reaches physicians and other prescribers through its own and contracted sales teams, national wholesalers and specialty distributors.
The timing of generic entry matters to that commercial business. Tonix identified potential harm to TONMYA sales from generic competition, along with litigation costs and demands on management’s attention, as risks.
Tonix also cautioned that patents could be found invalid, unenforceable or not infringed, and that the FDA could approve Dr. Reddy’s application or other generic applications.
The lawsuit has triggered a temporary approval pause; Tonix’s request for protection through patent expiration remains before the court.